Marloes Schaddelee

Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study

Marek Malík, E. Marcel van Gelderen, J H Lee et al. · Clinical Pharmacology & Therapeutics · 2012 · 147 citations

Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women

Walter Krauwinkel, Jan van Dijk, Marloes Schaddelee et al. · Clinical Therapeutics · 2012 · 96 citations

Elderly Men, Pharmacological Study, Pharmacology +8

Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers

Shin Takusagawa, Jan Jaap van Lier, Katsuhiro Suzuki et al. · Drug Metabolism and Disposition · 2012 · 62 citations

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder

Charlotte Eltink, Jennifer Lee, Marloes Schaddelee et al. · International Journal of Clinical Pharmacology and Therapeutics · 2012 · 54 citations

The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol

Walter Krauwinkel, James Dickinson, Marloes Schaddelee et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2013 · 45 citations

Molecular Pharmacology, Pharmacological Study, Drug Discovery +10